2 Drug Stocks Gapping Lower After Earnings

Both Cowen and Stifel downgraded AKCA stock

Feb 27, 2018 at 9:28 AM
facebook X logo linkedin


Clovis Oncology Inc (NASDAQ:CLVS) last night reported an adjusted fourth-quarter loss of $1.27 per share on $17 million in revenue, with the latter number falling short of analysts' consensus estimate for $20.1 million in revenue. Wall Street was quick to chime in, too, with CLVS stock receiving price-target cuts from Barclays (to $85), BofA-Merrill Lynch (to $89), Stifel (to $110), and SunTrust Robinson (to $85). And though all of these price targets sit well above last night's close at $55.51, the shares are down 2.4% in electronic trading.

Just last week, Clovis Oncology shares rallied on positive signs for its ovarian cancer drug marketing application in the European Union (EU), but were quickly contained by their 60-day moving average. This trendline has kept a tight lid on CLVS stock since early November, with the stock now staring at a six-month deficit of nearly 25%.

There's still plenty of optimism priced into CLVS shares, though. Of the 12 analysts covering the biotech, 10 maintain a "buy" or better rating, while the average 12-month price target of $86.55 stands at a 55.9% premium to current trading levels.

Akcea Therapeutics Inc (NASDAQ:AKCA) also reported earnings last night, with the lipid disorder specialist reporting a fourth-quarter loss of 35 cents per share and revenue of $18 million. The results prompted downgrades to the equivalent of a "hold" at both Cowen and Company and Stifel, though BMO raised its price target to $30 from $25.

After closing last night at $22.58, AKCA stock is down 21.2% in electronic trading -- on track to open at its lowest point since mid-January. Short sellers were betting on a pullback, too. Short interest on Akcea Therapeutics stock shot up 48.4% in the two most recent reporting period to a record high 5.14 million shares. These bearish bettors will be sitting on the sidelines today, though, with the security all but certain to land on the short-sale restricted list.

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI